| dc.contributor.author | Valicenti, RK | |
| dc.contributor.author | Perets, R | |
| dc.contributor.author | Lopez, J | |
| dc.contributor.author | Danson, S | |
| dc.contributor.author | Joensuu, HT | |
| dc.contributor.author | Peer, A | |
| dc.contributor.author | Harris, SJ | |
| dc.contributor.author | Souza, F | |
| dc.contributor.author | Ploeger, B | |
| dc.contributor.author | Pereira, KMC | |
| dc.contributor.author | Geva, R | |
| dc.coverage.spatial | San Diego, CA | |
| dc.date.accessioned | 2018-02-20T12:20:04Z | |
| dc.date.issued | 2017-10-01 | |
| dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411559102101&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
| dc.identifier.citation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (2), pp. E269 - E269 (1) | |
| dc.identifier.issn | 0360-3016 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1409 | |
| dc.identifier.eissn | 1879-355X | |
| dc.identifier.doi | 10.1016/j.ijrobp.2017.06.1245 | |
| dc.format.extent | E269 - E269 (1) | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER SCIENCE INC | |
| dc.subject | Science & Technology | |
| dc.subject | Life Sciences & Biomedicine | |
| dc.subject | Oncology | |
| dc.subject | Radiology, Nuclear Medicine & Medical Imaging | |
| dc.title | Safety of Radium-223+Paclitaxel in Cancer Patients with Bone Metastases: Results from an Open-Label, Multicenter Phase 1b Study | |
| dc.type | Other | |
| rioxxterms.versionofrecord | 10.1016/j.ijrobp.2017.06.1245 | |
| rioxxterms.licenseref.startdate | 2017-10-01 | |
| rioxxterms.type | Other | |
| dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | |
| pubs.finish-date | 2017-09-27 | |
| pubs.issue | 2 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.start-date | 2017-09-24 | |
| pubs.volume | 99 | en_US |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Medicine (de Bono Prostate) | en_US |
| dc.contributor.icrauthor | Lopez, Juanita | en |
| dc.contributor.icrauthor | Marsden, | en |
